fondaparinux 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
synthetic heparinoids 1236 104993-28-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fondaparinux
  • fondaparin
  • heparin pentasaccharide
  • fondaparinux sodium
  • arixtra
  • fondaparin sodium
Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.
  • Molecular weight: 1508.22
  • Formula: C31H53N3O49S8
  • CLOGP: -10.96
  • LIPINSKI: 3
  • HAC: 52
  • HDO: 19
  • TPSA: 805.48
  • ALOGS: -2.28
  • ROTB: 27

Drug dosage:

DoseUnitRoute
2.50 mg P

ADMET properties:

PropertyValueReference
CL (Clearance) 0.07 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.21 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 19.30 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 20 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ
Vd (Volume of distribution) 0.14 L/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
BA (Bioavailability) 1 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
Dec. 7, 2001 FDA MYLAN IRELAND LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haematoma 645.69 17.87 233 9896 34587 63444306
Muscle haemorrhage 356.33 17.87 86 10043 3093 63475800
Pulmonary embolism 276.14 17.87 192 9937 116492 63362401
Anaemia 233.12 17.87 259 9870 293171 63185722
Shock haemorrhagic 178.44 17.87 65 10064 9830 63469063
Cerebral haemorrhage 174.25 17.87 89 10040 30640 63448253
Heparin-induced thrombocytopenia 166.36 17.87 51 10078 4531 63474362
Incorrect product administration duration 165.11 17.87 64 10065 11482 63467411
Deep vein thrombosis 142.05 17.87 113 10016 83687 63395206
Haemorrhage 133.81 17.87 96 10033 60926 63417967
Post procedural haemorrhage 131.35 17.87 49 10080 7915 63470978
Haemoglobin decreased 124.75 17.87 134 9995 145351 63333542
Melaena 124.69 17.87 71 10058 30294 63448599
Intra-abdominal haematoma 123.81 17.87 33 10096 1772 63477121
Post procedural haematoma 119.83 17.87 30 10099 1255 63477638
Retroperitoneal haematoma 103.94 17.87 32 10097 2881 63476012
Subcutaneous haematoma 97.24 17.87 27 10102 1691 63477202
Subdural haematoma 94.47 17.87 46 10083 14282 63464611
Thrombocytopenia 84.49 17.87 112 10017 151045 63327848
Abdominal wall haematoma 81.91 17.87 27 10102 3028 63475865
Incision site haematoma 77.06 17.87 13 10116 67 63478826
Compartment syndrome 76.89 17.87 24 10105 2260 63476633
Haematemesis 76.30 17.87 52 10077 30360 63448533
Hypersensitivity myocarditis 76.19 17.87 15 10114 201 63478692
Thrombosis 66.88 17.87 66 10063 64689 63414204
Haemorrhage subcutaneous 66.70 17.87 23 10106 2960 63475933
Blood loss anaemia 65.72 17.87 31 10098 8970 63469923
Tooth erosion 54.02 17.87 13 10116 460 63478433
Extradural haematoma 53.42 17.87 17 10112 1705 63477188
Fatigue 52.89 17.87 39 10090 887989 62590904
Intra-abdominal haemorrhage 47.41 17.87 17 10112 2452 63476441
Incision site haemorrhage 46.38 17.87 12 10117 573 63478320
Thrombocytosis 42.35 17.87 20 10109 5798 63473095
Pulpitis dental 40.90 17.87 12 10117 916 63477977
Gastrointestinal haemorrhage 39.04 17.87 56 10073 81120 63397773
Hypovolaemic shock 38.04 17.87 19 10110 6222 63472671
Skin necrosis 35.32 17.87 24 10105 13926 63464967
Haemoperitoneum 34.97 17.87 14 10115 2727 63476166
Rectal haemorrhage 34.80 17.87 41 10088 48989 63429904
Toxic skin eruption 34.62 17.87 23 10106 12862 63466031
Cerebral haematoma 34.20 17.87 15 10114 3668 63475225
Abdominal wall haemorrhage 32.24 17.87 7 10122 155 63478738
Renal failure 32.15 17.87 63 10066 117589 63361304
Intraventricular haemorrhage 31.17 17.87 12 10117 2108 63476785
Oesophageal candidiasis 30.90 17.87 16 10113 5647 63473246
Red blood cell count decreased 30.53 17.87 35 10094 40610 63438283
Abdominal discomfort 30.36 17.87 7 10122 320878 63158015
Shock 30.12 17.87 27 10102 23436 63455457
Periodontitis 29.21 17.87 13 10116 3290 63475603
Wound haemorrhage 29.18 17.87 12 10117 2504 63476389
Gastric haemorrhage 29.07 17.87 16 10113 6382 63472511
Splenic rupture 28.69 17.87 10 10119 1328 63477565
Drug intolerance 28.68 17.87 7 10122 308654 63170239
Injection site haematoma 28.08 17.87 16 10113 6816 63472077
Retroperitoneal haemorrhage 27.96 17.87 12 10117 2785 63476108
Drug interaction 27.79 17.87 90 10039 229041 63249852
Pain 27.17 17.87 48 10081 740580 62738313
Venous thrombosis limb 27.12 17.87 12 10117 2996 63475897
Hepatic infarction 26.52 17.87 8 10121 672 63478221
Haematocrit decreased 26.44 17.87 32 10097 39308 63439585
Headache 26.07 17.87 38 10091 633203 62845690
Hemiplegia 25.92 17.87 17 10112 9306 63469587
Contraindicated product administered 24.43 17.87 3 10126 217645 63261248
Abdominal pain 24.40 17.87 102 10027 293354 63185539
Hypoperfusion 24.08 17.87 9 10120 1458 63477435
Drug hypersensitivity 23.64 17.87 10 10119 310677 63168216
Postoperative wound complication 23.57 17.87 8 10121 981 63477912
Spinal cord compression 23.44 17.87 12 10117 4136 63474757
Hepatic function abnormal 23.00 17.87 29 10100 37113 63441780
Prothrombin level decreased 22.97 17.87 7 10122 608 63478285
Drug ineffective 22.78 17.87 88 10041 1044677 62434216
Weight increased 22.19 17.87 7 10122 260785 63218108
Haemoptysis 22.02 17.87 25 10104 28701 63450192
Platelet count increased 21.98 17.87 20 10109 17691 63461202
Post procedural swelling 21.95 17.87 6 10123 354 63478539
Procedural haemorrhage 21.93 17.87 10 10119 2678 63476215
Insomnia 21.79 17.87 4 10125 215248 63263645
Rash maculo-papular 21.52 17.87 26 10103 31870 63447023
Sinusitis 21.32 17.87 5 10124 226648 63252245
Joint swelling 21.26 17.87 13 10116 327653 63151240
Nephropathy toxic 20.94 17.87 15 10114 9464 63469429
Spontaneous haematoma 20.41 17.87 7 10122 886 63478007
Traumatic haematoma 20.40 17.87 8 10121 1477 63477416
Haematuria 20.05 17.87 24 10105 29133 63449760
Breast haematoma 19.92 17.87 5 10124 211 63478682
Vulvovaginal injury 19.79 17.87 6 10123 512 63478381
Pelvic venous thrombosis 19.10 17.87 8 10121 1747 63477146
Haemodynamic instability 19.06 17.87 14 10115 9176 63469717
Brain herniation 18.95 17.87 10 10119 3667 63475226
Gastric ulcer haemorrhage 18.86 17.87 11 10118 4897 63473996
Arthralgia 18.19 17.87 40 10089 569670 62909223
Nasopharyngitis 18.06 17.87 9 10120 254248 63224645

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haematoma 211.27 18.90 102 6725 25503 34924601
Incorrect product administration duration 194.77 18.90 61 6766 4750 34945354
Muscle haemorrhage 133.35 18.90 43 6784 3675 34946429
Heparin-induced thrombocytopenia 119.83 18.90 44 6783 5551 34944553
Cerebral haemorrhage 100.09 18.90 70 6757 34867 34915237
Pulmonary embolism 99.27 18.90 104 6723 89642 34860462
Anaemia 96.56 18.90 167 6660 233168 34716936
Haemorrhage 94.41 18.90 79 6748 51291 34898813
Shock haemorrhagic 86.83 18.90 43 6784 11311 34938793
Post procedural haemorrhage 68.18 18.90 33 6794 8256 34941848
Haematoma muscle 62.32 18.90 19 6808 1349 34948755
Ureteric compression 58.19 18.90 13 6814 267 34949837
Post procedural haematoma 56.14 18.90 18 6809 1508 34948596
Subdural haematoma 54.01 18.90 39 6788 20382 34929722
Melaena 52.07 18.90 48 6779 35332 34914772
Deep vein thrombosis 47.44 18.90 61 6766 65187 34884917
Haematuria 44.81 18.90 52 6775 50014 34900090
Thrombocytosis 41.94 18.90 19 6808 4093 34946011
Haematemesis 41.55 18.90 38 6789 27673 34922431
Thrombocytopenia 40.32 18.90 92 6735 156155 34793949
Pyelocaliectasis 40.22 18.90 13 6814 1117 34948987
Extradural haematoma 39.57 18.90 13 6814 1176 34948928
Thrombosis 39.56 18.90 49 6778 50409 34899695
Retroperitoneal haematoma 35.88 18.90 15 6812 2663 34947441
Retroperitoneal haemorrhage 34.79 18.90 15 6812 2873 34947231
Intra-abdominal haematoma 33.92 18.90 12 6815 1358 34948746
Adrenal haemorrhage 33.68 18.90 8 6819 217 34949887
Gastrointestinal haemorrhage 33.36 18.90 61 6766 88416 34861688
Haemoglobin decreased 33.24 18.90 73 6754 120699 34829405
Spinal cord haemorrhage 30.57 18.90 8 6819 325 34949779
Abdominal wall haematoma 30.49 18.90 12 6815 1825 34948279
Venous thrombosis 26.22 18.90 13 6814 3422 34946682
Altered state of consciousness 26.06 18.90 27 6800 22866 34927238
Haemorrhage intracranial 24.15 18.90 22 6805 15924 34934180
Lumbosacral plexus injury 23.54 18.90 4 6823 17 34950087
Haemorrhagic stroke 23.24 18.90 15 6812 6524 34943580
Cerebral haematoma 22.61 18.90 13 6814 4602 34945502
Subacute cutaneous lupus erythematosus 21.89 18.90 8 6819 994 34949110
Intra-abdominal haemorrhage 21.06 18.90 10 6817 2394 34947710
Haemarthrosis 20.99 18.90 11 6816 3248 34946856
Haemothorax 19.27 18.90 11 6816 3841 34946263
Gastric haemorrhage 19.26 18.90 16 6811 10245 34939859
Purpura 19.19 18.90 16 6811 10295 34939809
Coma 19.13 18.90 33 6794 45645 34904459

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haematoma 639.40 18.13 260 12773 51935 79679420
Muscle haemorrhage 300.31 18.13 87 12946 6213 79725142
Pulmonary embolism 292.05 18.13 234 12799 171420 79559935
Heparin-induced thrombocytopenia 255.47 18.13 85 12948 9597 79721758
Cerebral haemorrhage 245.13 18.13 139 12894 57534 79673821
Anaemia 230.71 18.13 321 12712 444694 79286661
Incorrect product administration duration 218.73 18.13 80 12953 11942 79719413
Shock haemorrhagic 191.98 18.13 84 12949 19976 79711379
Haemorrhage 162.74 18.13 128 12905 90990 79640365
Deep vein thrombosis 156.39 18.13 141 12892 120778 79610577
Post procedural haemorrhage 129.69 18.13 57 12976 13687 79717668
Post procedural haematoma 122.03 18.13 35 12998 2407 79728948
Melaena 120.60 18.13 91 12942 60799 79670556
Haematemesis 101.03 18.13 77 12956 52187 79679168
Intra-abdominal haematoma 99.20 18.13 31 13002 2860 79728495
Subdural haematoma 95.19 18.13 61 12972 31373 79699982
Thrombosis 93.09 18.13 90 12943 84010 79647345
Thrombocytopenia 90.19 18.13 158 12875 265101 79466254
Retroperitoneal haematoma 84.42 18.13 32 13001 5265 79726090
Subcutaneous haematoma 79.73 18.13 26 13007 2751 79728604
Abdominal wall haematoma 79.69 18.13 30 13003 4843 79726512
Haemoglobin decreased 78.99 18.13 135 12898 221984 79509371
Extradural haematoma 74.84 18.13 25 13008 2851 79728504
Hypersensitivity myocarditis 72.60 18.13 15 13018 253 79731102
Haematoma muscle 69.12 18.13 23 13010 2592 79728763
Blood loss anaemia 64.80 18.13 37 12996 15461 79715894
Thrombocytosis 63.51 18.13 30 13003 8496 79722859
Haematuria 60.37 18.13 65 12968 68771 79662584
Ureteric compression 60.35 18.13 13 13020 270 79731085
Pyelocaliectasis 53.99 18.13 15 13018 918 79730437
Incision site haemorrhage 51.74 18.13 15 13018 1071 79730284
Tooth erosion 50.39 18.13 12 13021 396 79730959
Compartment syndrome 47.68 18.13 21 13012 5061 79726294
Gastrointestinal haemorrhage 42.54 18.13 82 12951 147637 79583718
Fatigue 41.42 18.13 55 12978 929672 78801683
Adrenal haemorrhage 40.67 18.13 11 13022 609 79730746
Drug interaction 40.36 18.13 154 12879 415029 79316326
Skin necrosis 40.20 18.13 29 13004 18058 79713297
Brain herniation 40.00 18.13 21 13012 7442 79723913
Retroperitoneal haemorrhage 39.98 18.13 19 13014 5451 79725904
Haemorrhage subcutaneous 39.16 18.13 18 13015 4791 79726564
Toxicity to various agents 37.84 18.13 11 13022 421529 79309826
Gastric haemorrhage 37.79 18.13 26 13007 15024 79716331
Spinal cord haemorrhage 36.79 18.13 10 13023 564 79730791
Pulpitis dental 36.51 18.13 12 13021 1301 79730054
Injection site haematoma 36.00 18.13 17 13016 4810 79726545
Wound haemorrhage 35.22 18.13 16 13017 4145 79727210
Altered state of consciousness 34.30 18.13 39 12994 43783 79687572
Toxic skin eruption 32.77 18.13 28 13005 22265 79709090
Haemorrhage intracranial 32.72 18.13 30 13003 26163 79705192
Hypovolaemic shock 32.71 18.13 22 13011 12254 79719101
Incision site haematoma 32.42 18.13 7 13026 147 79731208
Rectal haemorrhage 31.96 18.13 50 12983 76250 79655105
Haemothorax 31.04 18.13 16 13017 5462 79725893
Nasopharyngitis 30.67 18.13 3 13030 253878 79477477
Drug intolerance 29.71 18.13 4 13029 264115 79467240
Off label use 28.75 18.13 249 12784 906966 78824389
Haemoperitoneum 28.46 18.13 14 13019 4329 79727026
Weight increased 27.26 18.13 6 13027 277380 79453975
Coma 26.69 18.13 54 12979 100595 79630760
Oesophageal candidiasis 25.71 18.13 17 13016 9201 79722154
Eosinophilia 25.23 18.13 34 12999 45311 79686044
Haemorrhagic stroke 25.21 18.13 18 13015 11028 79720327
Venous thrombosis limb 25.20 18.13 13 13020 4444 79726911
Venous thrombosis 24.53 18.13 15 13018 7101 79724254
Lumbosacral plexus injury 24.25 18.13 4 13029 17 79731338
Acute coronary syndrome 24.08 18.13 23 13010 21110 79710245
Hepatic infarction 23.99 18.13 8 13025 907 79730448
Pain 22.70 18.13 51 12982 703751 79027604
Rash maculo-papular 22.45 18.13 36 12997 56042 79675313
Periodontitis 22.26 18.13 12 13021 4484 79726871
Haemarthrosis 21.97 18.13 13 13020 5799 79725556
Abdominal discomfort 21.65 18.13 7 13026 250720 79480635
Drug hypersensitivity 21.51 18.13 11 13022 298905 79432450
Cross sensitivity reaction 21.49 18.13 11 13022 3701 79727654
Abdominal pain 21.14 18.13 122 12911 389447 79341908
Haemoptysis 21.13 18.13 35 12998 55964 79675391
Spinal cord compression 20.85 18.13 13 13020 6364 79724991
Cough 20.36 18.13 18 13015 366771 79364584
Postoperative wound complication 20.06 18.13 8 13025 1506 79729849
Upper gastrointestinal haemorrhage 20.00 18.13 29 13004 41351 79690004
Haemodynamic instability 19.96 18.13 19 13014 17363 79713992
Electrocardiogram QT prolonged 19.93 18.13 45 12988 90341 79641014
Product dose omission issue 19.53 18.13 8 13025 247529 79483826
Intra-abdominal haemorrhage 19.41 18.13 11 13022 4529 79726826
Brain stem haemorrhage 19.39 18.13 8 13025 1642 79729713
Insomnia 19.22 18.13 8 13025 245162 79486193
Procedural haemorrhage 19.04 18.13 11 13022 4695 79726660
Renal failure 19.02 18.13 74 12959 200894 79530461
Gastric ulcer haemorrhage 18.98 18.13 14 13019 9013 79722342
Infusion related reaction 18.89 18.13 7 13026 230230 79501125
Hypoperfusion 18.78 18.13 9 13024 2630 79728725
Intraventricular haemorrhage 18.65 18.13 11 13022 4876 79726479
Hemiplegia 18.44 18.13 17 13016 14922 79716433
Cerebellar haematoma 18.44 18.13 6 13027 630 79730725
Vulvovaginal injury 18.36 18.13 5 13028 284 79731071
Necrosis 18.36 18.13 14 13019 9479 79721876
Cerebral haematoma 18.26 18.13 13 13020 7929 79723426
Ecchymosis 18.18 18.13 17 13016 15189 79716166

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AX05 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Other antithrombotic agents
MeSH PA D000925 Anticoagulants
MeSH PA D000991 Antithrombins
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D065427 Factor Xa Inhibitors
MeSH PA D006401 Hematologic Agents
MeSH PA D011480 Protease Inhibitors
MeSH PA D015842 Serine Proteinase Inhibitors
FDA MoA N0000175635 Factor Xa Inhibitors
FDA EPC N0000175637 Factor Xa Inhibitor
CHEBI has role CHEBI:50249 anticoagulants

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Deep venous thrombosis indication 128053003
Pulmonary thromboembolism indication 233935004
Prevention of deep vein thrombosis indication 439993001
Myocardial infarction off-label use 22298006 DOID:5844
Acute coronary syndrome off-label use 394659003
Diabetic retinopathy contraindication 4855003 DOID:8947
Gastrointestinal ulcer contraindication 40845000
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Operation on brain contraindication 70586009
Heparin-induced thrombocytopenia contraindication 73397007
Kidney disease contraindication 90708001 DOID:557
Autoimmune thrombocytopenia contraindication 128091003
Hemorrhagic cerebral infarction contraindication 230706003
Local anesthetic intrathecal block contraindication 231249005
Procedure on spine contraindication 238181003
Anemia contraindication 271737000 DOID:2355
Lumbar puncture contraindication 277762005
Bacterial endocarditis contraindication 301183007
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Surgical procedure on eye proper contraindication 373353005
Hypertensive urgency contraindication 443482000
Significant Bleeding contraindication
Platelet Aggregation Inhibition contraindication
Placement of Epidural Catheter contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.23 acidic
pKa2 0.94 acidic
pKa3 2.46 acidic
pKa4 3.08 acidic
pKa5 11.49 acidic
pKa6 11.98 acidic
pKa7 12.26 acidic
pKa8 12.43 acidic
pKa9 12.91 acidic
pKa10 13.69 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Antithrombin-III Secreted ACTIVATOR Kd 7.49 IUPHAR CHEMBL
Coagulation factor X Enzyme IC50 7 CHEMBL

External reference:

IDSource
4021296 VUID
N0000148733 NUI
D01844 KEGG_DRUG
114870-03-0 SECONDARY_CAS_RN
4021296 VANDF
C1098510 UMLSCUI
CHEBI:61033 CHEBI
NTO PDB_CHEM_ID
CHEMBL1201202 ChEMBL_ID
CHEMBL1276258 ChEMBL_ID
CHEMBL1200644 ChEMBL_ID
D000077425 MESH_DESCRIPTOR_UI
DB00569 DRUGBANK_ID
C049714 MESH_SUPPLEMENTAL_RECORD_UI
6819 IUPHAR_LIGAND_ID
J177FOW5JL UNII
5282448 PUBCHEM_CID
321208 RXNORM
16268 MMSL
184641 MMSL
18938 MMSL
42652 MMSL
d04786 MMSL
009549 NDDF
009550 NDDF
385517000 SNOMEDCT_US
395236007 SNOMEDCT_US
708189008 SNOMEDCT_US
7653 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3443 INJECTION 2.50 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3454 INJECTION 5 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3465 INJECTION 7.50 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3476 INJECTION 10 mg SUBCUTANEOUS ANDA 27 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 11797-154 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS ANDA 28 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 11797-155 INJECTION, SOLUTION 5 mg SUBCUTANEOUS ANDA 28 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 11797-156 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS ANDA 28 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 11797-157 INJECTION, SOLUTION 10 mg SUBCUTANEOUS ANDA 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43598-606 INJECTION 10 mg SUBCUTANEOUS ANDA 26 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43598-606 INJECTION 10 mg SUBCUTANEOUS ANDA 26 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43598-607 INJECTION 2.50 mg SUBCUTANEOUS ANDA 26 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43598-607 INJECTION 2.50 mg SUBCUTANEOUS ANDA 26 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43598-608 INJECTION 5 mg SUBCUTANEOUS ANDA 26 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43598-608 INJECTION 5 mg SUBCUTANEOUS ANDA 26 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43598-609 INJECTION 7.50 mg SUBCUTANEOUS ANDA 26 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43598-609 INJECTION 7.50 mg SUBCUTANEOUS ANDA 26 sections
ARIXTRA HUMAN PRESCRIPTION DRUG LABEL 1 54868-5501 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA 27 sections
ARIXTRA HUMAN PRESCRIPTION DRUG LABEL 1 54868-5652 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55111-678 INJECTION 2.50 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55111-679 INJECTION 5 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55111-680 INJECTION 7.50 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55111-681 INJECTION 10 mg SUBCUTANEOUS ANDA 27 sections
FONDAPARINUX SODIUM Human Prescription Drug Label 1 55150-230 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS ANDA 28 sections
FONDAPARINUX SODIUM Human Prescription Drug Label 1 55150-231 INJECTION, SOLUTION 5 mg SUBCUTANEOUS ANDA 28 sections
FONDAPARINUX SODIUM Human Prescription Drug Label 1 55150-232 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS ANDA 28 sections
FONDAPARINUX SODIUM Human Prescription Drug Label 1 55150-233 INJECTION, SOLUTION 10 mg SUBCUTANEOUS ANDA 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-582 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS NDA authorized generic 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-583 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA authorized generic 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-584 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA authorized generic 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-585 INJECTION, SOLUTION 10 mg SUBCUTANEOUS NDA authorized generic 28 sections